Testimonials
What our clients think of our cost-effective clinical trials and strategies that nurture product strengths
Catherine Stehman-Breen, MD
CMO, Sarepta Therapeutic
Her deep knowledge of rare disease and the complexities of conducting research in rare disease was clear through her high-quality deliverables.
Maria Roche, NP
Medical Director, Clinical Research, Epizyme, Inc.
Thank you for your efforts here at Epizyme helping us evaluate our pharmacovigilance needs. You provided useful insights into how to operationalize pharmacovigilance activities as our clinical program rapidly expands. Your depth of experience in both clinical and PV provided an important perspective as we integrate the safety of all our programs into a unified database.
Iman Elhariry, MD, PhD
CMO, Erytech Pharma
Many thanks for all the work over the past year. It was a pleasure working with you and I hope our path crossed again in the future….
Patrick J. Crutcher
CEO, Ichorion Therapeutics, Inc.
[BBCR] brought a strong track record of experience developing treatments for rare diseases. [Their] background made them an excellent fit for our programs, especially from a clinical and regulatory point-of-view. I would recommend [BBCR] for their ability to effectively build clinical development programs and provide unique support for regulatory interactions.
Maria Roche, NP
Medical Director, Clinical Research, Epizyme, Inc.
I want to thank you [BBCR] for your efforts here at Epizyme helping us evaluate our pharmacovigilance needs. You provided useful insights into how to operationalize pharmacovigilance activities as our clinical program rapidly expands. Your depth of experience in both clinical and PV provided an important perspective as we integrate the safety of all our programs into a unified database. I enjoyed working with you and look forward to future collaborations.
Christa Bleyleben
Managing Partner at MassGlobal Partners
[BBCR’s] Candida Fratazzi is a true visionary in clinical research and excels in problem solving by offering novel and realistic solutions to often complex challenges, resulting in highly effective, yet cost efficient outcomes for her clients. I was also impressed by her ability to seamlessly work with very diversified teams. Dr. Fratazzi is a great asset to any company interested in innovative approaches to clinical research and I can highly recommend to partner with her.
Jess Rabourn, CFA
Managing Director, ALS Emergency Treatment Fund
[BBCR] brings a track record of success developing treatments for rare diseases. It was this background and their specific expertise in trial design and regulatory affairs that made them the perfect fit for our pharmaceutical licensing platform, where she has served as a board member and medical officer. I strongly recommend [BBCR] for their innovative approach to clinical development strategies.
Celeste DiJohnson
Vice President, Clinical Operations at Sarepta Pharmaceuticals
Our Clinical team thoroughly enjoyed working with [BBCR], they were able to integrate into the team with ease and made positive and important contributions to our clinical development priority initiatives. {BBCR] interfaced extremely well with clinical sites, CROs and all internal Sarepta Therapeutics multi-functional teams.
Jannine Williams
Senior Director, Program Leader at Momenta Pharmaceuticals
BBCR’s Candida Fratazzi was hired as the medical lead on a cross functional team I led, which was preparing for a biosmilar BLA submission. Dr. Fratazzi seamlessly integrated into the program and quickly developed good working relationships with many on the team. During this time, I observed her being particularly good at synthesizing data quickly/on the spot. I have learned many things from working along side of her. It is clear that she cares deeply for her clients and for patients.
David Whiteman
Global Development Team Lead, Neurogenetics/Rare Diseases at Shire
[BBCR] is an innovative designer of clinical research programs. They have the vision to see through the details of complex clinical and regulatory strategy issues, and comes up with practical and innovative solutions. They engages effortlessly with people of different backgrounds and cultures, and leads though her effective example. [BBCR] provides an important resource in drug development design strategy.
Takeaki Suzuki, PhD
Associate Director, Drug Development
Head of Operations, FUJIFILM Pharmaceuticals U.S.A., Inc.
[BBCR] brings a track record of success developing treatments for rare diseases. It was this background and their specific expertise in trial design and regulatory affairs that made them the perfect fit for our pharmaceutical licensing platform. I strongly recommend [BBCR] for their innovative approach to clinical development strategies.